Israel has become the first county in the world to grant medical device approval to a vaporizer for the use of medical cannabis extracts and formulations.

The Israeli Ministry of Health has granted initial approval as a medical device to the VapePod vaporizer developed by Kanabo Research, a Tel-Aviv-based medical cannabis R&D company.

The company claims that the combination of the approved vaporizer and the targeted formulations will enable medical cannabis patients to receive more effective, consistent, and accurate dosing and delivery methods than currently accepted medical cannabis treatment methods.

Most medical cannabis patients today consume their cannabis by smoking. VapePod removes the risks of smoking and has been proven more effective than other delivery methods.

“This approval is a significant announcement for the medical cannabis patients in Israel who will be able to use the medical vaporizer for the first time,” said Avihu Tamir, cofounder and CEO of Kanabo Research.

“We expect that due to the transition of most of the cannabis consumers to the use of vaporizers, our company is projected to reach $10 million in sales within three years in the Israeli market, while the Israeli cannabis market is expected to reach $100 million in sales within three years. The Israeli market is a platform to deliver our technology to global markets in North America and Europe.”

Kanabo has initiated initial preclinical trials of the company’s targeted formulations for sleep disorders, designed for use with VapePod. It is also preparing the next version of the device, VapePod MD, which will monitor patient usage and gather usage data for caregivers, doctors and research applications.